Predictive Technology Group, Inc.’s (PRED) Subsidiary Provides a Sponsorship at 4th Annual Perinatal Stem Cell Society Congress

Salt Lake City, UT- March 5, 2018- Predictive Biotech, Inc., a wholly owned subsidiary of Predictive Technology Group, Inc. (PRED.OTCPINK) provided a sponsorship at the 4th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT on March 1-2, 2018.

In 2013, the Perinatal Stem Cell Society, Inc. a non-profit organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders. Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue

Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc., presented an oral presentation to the society titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?”

Dr. Schmid received his Ph.D. in Physiology from the University of Utah School of Medicine in Salt Lake City, Utah. He completed four years of post-doctoral training at the University of Utah Medical School and five years as a Research Associate at the University of Utah Medical School as a cellular biologist. Dr. Schmid has 23 years of experience in primary cell culture, tissue processing and cryogenic storage of cells and tissues. After working at the University of Utah, from 2009 to present, Dr. Schmid has established, implemented, and supervised the operational aspects of several tissue companies, including the recovery, quality control, processing, and distribution of tissue. He is passionate about quality and vitality of physiological products and the vast benefits they deliver.

Predictive Technology Group, Inc. wholly owned subsidiary, Predictive Biotech, Inc. is in the business of developing advancements in human cell and tissue products. Data collected in collaboration with other research institutes and clients are the cornerstone in Predictive Biotech’s product development.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) RETAINS DONOHOE ADVISORY ASSOCIATES LLC, TO ASSIST IN PREPARING TO SEEK A LISTING ON A NATIONAL SECURITIES EXCHANGE

Salt Lake City, UT- February 27, 2018- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange.

Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”). Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.

Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it is well positioned to pursue a listing on a recognized exchange. Hiring Donohoe Advisory will help to further this effort.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES COMPLETION OF GENOTYPING IN TWO CLINICAL TRIALS OF ARTGUIDE™

Salt Lake City, UT — February 20, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Predictive Therapeutics, LLC, its wholly-owned subsidiary, completed a crucial milestone in the development and commercialization of ARTGuide™.

The Company’s scientific team completed the genotyping in two clinical trials of ARTGuide™. As such, Company representatives are providing three scientific presentations at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI) on March 9th and 10th in San Diego, CA.

Predictive Therapeutics, LLC anticipates its launch of a novel test for women experiencing infertility, as a result of endometriosis and other health concerns, called ARTGuide™. The test is expected to change the way Advanced Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), are used to help couples struggling to have a baby. After testing thousands of women as part of the development program, the Company now expects commercial launch of the ARTGuide™ infertility test in the United States during Q3 2018.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis and pelvic pain.

PRED and its subsidiaries remain leaders in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body -most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Predictive Technology Group, Inc.:
Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Pelvic Pain, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) APPOINTS RONALD BARHORST TO CHAIR ITS FINANCIAL ADVISORY BOARD

Salt Lake City, UT — January 30, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that its Financial Advisory Board appointed Mr. Ronald Barhorst as Chairman. Mr. Barhorst brings in depth finance and governance experience gained during a career in the financial markets.

In January 2013, after 25 years in the financial services industry, Mr. Barhorst retired as President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman of the California State University Foundation Board of Governors, a position he has held for the past 15 years.

“I have had the opportunity to work with Predictive Technology Group or their predecessor companies for the past 8 years,” said Ronald Barhorst. “I am impressed with the brilliant minds that drive this Company and the substantial impact that this Company represents in targeted gene based therapeutics and women’s health.”

“As we move forward to becoming a full-reporting company under the Securities Exchange Act of 1934, Ron’s wealth of experience, gained in senior executive roles in the financial industry, will help ensure PRED maintains proper governance, oversight and guidance through its Board and Committees,” said Bradley Robinson, CEO of Predictive Technology Group.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. GREGORY A. PRINCE TO ITS SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 17, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that Dr. Gregory A. Prince will join PRED’s Scientific Advisory Board.  As a co-founder and CEO of Virion Systems, Inc., Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.

After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.

“I welcome Greg to the PRED team.  His vision and experience in applying data analytics for disease identification and understanding of the individual will help ensure each and every patient receives the most appropriate therapy at the earliest possible point of intervention,” said Bradley Robinson, CEO, Predictive Technology Group, Inc. “Dr. Prince has already contributed greatly to society and the health of newborns, he is passionate about applying his career knowledge to improve quality of life in other population groups.”

Dixie State University-St. George, Utah inducted Dr. Prince to its Hall of Fame in 1999, in recognition of his scientific achievements, and later in 2012, the university granted him an honorary Doctorate of Humanities.  Dr. Prince serves on the national advisory councils at four universities, and as the governor of Wesley Theological Seminary in Washington, D.C. He holds adjunct professorships at UCLA and Dixie State University and currently serves as Chief Scientific Officer at Soft Cell Biological Research, LLC.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP (PRED) APPOINTS JOHN C. NELSON, M.D., M.P.H. TO THE PREDICTIVE TECHNOLOGY GROUP SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 11, 2018 — Predictive Technology Group, Inc. (OTCPINK: PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group Scientific Advisory Board.  Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.

Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society and, the Utah Medical Association.  Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ).  As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.

Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education.  As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.

Dr. Nelson’s civic involvement includes time on the advisory committee of the local Boys and Girls Club of Salt Lake City, the Christmas Box House board, and the board of Operation Kids.

As PRED continues to advance its growth, Dr. Nelson’s vast medical, scientific, and business knowledge and experience brings a valued addition to the Company’s advisory team.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP FINALIZES LETTER OF INTENT TO ACQUIRE FLAGSHIPHEALTH GROUP

Salt Lake City, UT — January 9, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that it finalized an arrangement for the acquisition of FlagshipHealth Group, a Minneapolis-based provider of sales and consulting services for the healthcare industry.

The business combination provides essential resources for Predictive Technology Group to develop, launch, and grow its services directed at limiting disease and improving the health and well-being of individuals confronting a wide-range of medical conditions. Since February 2017, Flagship provided sales and marketing support for the successful launch of treatments offered by Predictive Technology Group’s wholly owned subsidiary Predictive Biotech one of the fastest growing regenerative medicine portfolios in the U.S.

FlagshipHealth Group also worked with Predictive Technology Group’s wholly owned subsidiary Predictive Therapeutics toward commercialization, in late 2018, of the ARTGuide™, a genetic diagnostic for endometriosis and other concerns addressed in fertility clinics, and FertilityDx™ Services, a test suite delivering personalized and comprehensive genetic diagnostic services to couples undergoing infertility care.

The seasoned and proven management team at FlagshipHealth Group brings diverse and deep experience in all areas of healthcare. The company focuses on delivering innovative and beneficial health and treatment approaches to people who can benefit from them, and in ways which help improve the services and efficiency of those providing care. FlagshipHealth Group, headed by President and Founder Tim Lacy, a veteran executive whose experience includes senior executive positions at UnitedHealth Group and Walgreens, and FlagshipHealth’s Michael Herbert, a seasoned healthcare veteran who has focused on the Predictive partnership since February of 2017. Also, William W. McGuire, M.D., the former Chairman and Chief Executive Officer of UnitedHealth Group for 17 years in its formative development and growth phase, provides Predictive Technology Group with strategic and tactical planning around healthcare issues and customer needs.

“We are very pleased to have the team at Flagship join the Predictive organization,” said Bradley Robinson, CEO of Predictive Technology Group. “As we move forward to fully address important challenges, such as endometriosis, and our efforts in regenerative health interventions, the team at Flagship demonstrates a tremendous understanding of the complexity and stakeholder diversity within healthcare delivery, finance and administration. With the expansion of our products and services addressing significant medical problems confronting individuals and families throughout the world and our imminent commercialization of diagnostics and therapeutics for endometriosis, it became obvious that the integration of our two organizations better serves patients, care providers, and shareholders.”

Commenting on the opportunities, Tim Lacy said, “We have enjoyed working closely with Predictive since our introduction in 2010, and through Predictive Biotech’s regenerative medicine commercialization in 2017.  We are excited to transition Flagship from a long-time advisory partner into a permanent contributor to the Predictive family.”

“Predictive’s business success will be directly linked to enhancing the well-being of the people it serves and its ability to improve the system within which it operates to address specific health challenges. This will be particularly true in association with the pending launch of products and services directed at the immense problems surrounding endometriosis, women’s health and the supporting health care delivery system – whether measured in terms of economic cost, patient morbidity, the needs of care providers or system efficiency,” said Dr. McGuire. “There is great potential in Predictive’s ability to positively influence an area of women’s health that has been largely underserved.”

In conjunction with significant additions to business management and its advisory group, the combined resources of FlagshipHealth Group, Predictive Technology Group and its subsidiaries, will be immediately directed at continued expansion of the regenerative medicine business and its efforts to assist women in overcoming the devastating consequences of endometriosis, including appropriate early-stage diagnosis and subsequent treatment.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

 

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. HUGH S. TAYLOR, M.D. TO THE PREDICTIVE TECHNOLOGY GROUP’S SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 4, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Dr. Hugh S. Taylor, M.D., joined the Predictive Technology Group’s Scientific Advisory Board. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale University, brings extensive clinical research and development expertise in endometriosis and women’s health to PRED’s Scientific Advisory Board team.

Dr. Taylor’s many accomplishments include Anita O’Keeffe Young Professor and Chairs Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics, and Gynecology at Yale-New Haven Hospital. He teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University. His clinical interests include endometriosis, infertility, implantation, Asherman’s syndrome, menopause and uterine anomalies.

Also, Dr. Taylor, a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology, received eight National Institutes of Health research grants. Dr. Taylor published more than 300 articles in leading medical journals, continues as the Editor-In-Chief of Reproductive Sciences, and elected to the membership of the National Academy of Medicine.

Dr. Taylor received his undergraduate training at Yale University and his medical degree from the University Of Connecticut School Of Medicine. He completed his residency in obstetrics and gynecology at Yale. His postdoctoral training included a fellowship in reproductive endocrinology and infertility, as well as, a fellowship in molecular biology, both at Yale.

Predictive plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. MICHAEL DEY TO BOARD OF DIRECTORS

CEO of Predictive Therapeutics and Former Wyeth Women’s Health Executive Joins Predictive Technology Group Board of Directors

Salt Lake City, UT — January 2, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), announces the appointment of Michael Dey, Ph.D. to the Board of Directors of Predictive Technology Group, Inc.  Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED subsidiaries.

In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED.  Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business.  As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.

“We are very pleased to have Mike join PRED’s Board of Directors,” said Bradley Robinson, CEO of PRED. “Mike’s breadth of knowledge and experience in life sciences will greatly assist in advancing science and technology and bringing related diagnostics and therapeutics to the clinic to improve the care and outcomes of patients.”

Before his leadership role in women’s health care, Dr. Dey served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Dr. Dey became President of ESI Lederle, Inc.  As President of ESI Lederle, Dr. Dey’s responsibilities included directing one of the largest generic companies in the U.S. with more than $500 million in sales, approximately 150 people in R&D and 100 people in marketing and sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system.

Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the treatment of endometriosis. Dr. Dey’s appointment will assist PRED to reach these commercial milestones effectively.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces Issuance of U.S. Patent for Method of Treating Endometriosis

Issuance Strengthens Commercialization Strategy of Company’s Gene-Based Endometriosis Diagnostics and Therapeutics

Salt Lake City, UT – December 28, 2017- Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today the issuance of U.S. patent 9,840,738 directed to treating patients genetically predisposed to endometriosis.

Endometriosis, a common gynecologic disorder estimated to affect 1 in 10 women in their reproductive years – equates to approximately 176 million women in the world.  U.S. patent 9,840,738, builds on the coverage provided by previously issued US patent 8,932,993

“This technology brings a significant opportunity for PRED and to the healthcare market, assisting women and their physicians in designing a course of care that places women on the most appropriate therapy at the earliest possible stage of disease progression,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to the therapeutic products PRED intends to bring to market.”

Bradley Robinson described the claims of U.S. patent 9,840,738 as covering any treatment of endometriosis in women, whether symptomatic or not, having any one (or more) of approximately 1,400 endometriosis-associated genetic markers.

About Predictive Technology Group, Inc. 

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding Company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.